A5088916415- Inflammatory Bowel Disease
- Immunodeficiency and Autoimmune Disorders
- Microscopic Colitis
- Gut microbiota and health
- Clostridium difficile and Clostridium perfringens research
- Eosinophilic Esophagitis
- Immune Cell Function and Interaction
- Helicobacter pylori-related gastroenterology studies
- Autoimmune and Inflammatory Disorders Research
- Adolescent and Pediatric Healthcare
- Gastrointestinal motility and disorders
- Mycobacterium research and diagnosis
- Intestinal Malrotation and Obstruction Disorders
- IL-33, ST2, and ILC Pathways
- Cytomegalovirus and herpesvirus research
- Pharmaceutical studies and practices
- Pancreatic and Hepatic Oncology Research
- Digestive system and related health
- Inflammasome and immune disorders
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Whipple's Disease and Interleukins
- Gastrointestinal disorders and treatments
- Pharmacological Effects of Natural Compounds
- Celiac Disease Research and Management
- Drug-Induced Hepatotoxicity and Protection
Children's Hospital of Philadelphia
2016-2025
University of Pennsylvania
2017-2025
Philadelphia University
2024
Altered plasma acylcarnitine levels are well-known biomarkers for a variety of mitochondrial fatty acid oxidation disorders and can be used as an alternative energy source the intestinal epithelium when short-chain acids low. These membrane-permeable intermediates excreted into gut lumen via bile increased in feces patients with inflammatory bowel disease (IBD).
The pharmacokinetics of biologic agents can differ between children and adults with inflammatory bowel disease (IBD), often necessitating modified paediatric dosing strategies. To define the exposure-response relationship vedolizumab in IBD VedoKids cohort including effect baseline clearance on deep biochemical remission (normal C-reactive protein [CRP]/erythrocyte sedimentation rate [ESR] steroid-free remission) at 30 weeks, to use population pharmacokinetic models find best matches adult...
There are scarce data available on upadacitinib in children with Crohn's disease (CD). To evaluate the effectiveness and safety of as an induction therapy paediatric CD. This was a multicentre retrospective study between 2022 2024 treated for remission active CD conducted 30 centres worldwide affiliated IBD Interest Porto group ESPGHAN. We recorded demographic, clinical laboratory adverse events (AEs) at week 8 post-induction. The analysis primary outcome based upon intention-to-treat (ITT)...
Vedolizumab is effective for inducing and maintaining remission in adults with inflammatory bowel disease (IBD); however, there limited pediatric data. This study aimed to describe the adverse events clinical response vedolizumab refractory IBD.Disease activity indices, response, concomitant medication use, were measured over 22 weeks an observational prospective cohort of children IBD who had failed anti-tumor necrosis factor therapy subsequently initiated therapy.Twenty-one subjects, 16...
Abstract Background and Aims Dysbiosis of the gut microbiota is a well-known correlate pathogenesis inflammatory bowel disease [IBD]. However, few studies have examined microbiome in very early-onset [VEO] IBD, which defined as onset IBD before 6 years age. Here we focus on viral portion microbiome—the virome—to assess possible associations with processes, reasoning that any viruses potentially associated might grow more robustly younger subjects, so be detectable. Methods Virus-like...
Abstract Background Insight into the pathogenesis of very early onset-inflammatory bowel disease (VEO-IBD) has expanded through identification causative monogenic defects detected in a subset patients. However, clinical course this population remains uncertain. The study objective is to determine whether VEO-IBD associated with more severe disease, defined as increased surgical intervention and growth failure, than older pediatric IBD. Secondary outcomes included therapeutic response...
Children with very early onset inflammatory bowel disease [VEO-IBD] represent a unique cohort, often severe phenotype that is refractory to conventional medications, and some cases have underlying primary immunodeficiencies. Previous work has identified distinct histopathological patterns in the gastrointestinal tract patients The aim of this study characterise diagnostic histological findings VEO-IBD as compared older paediatric IBD, determine if there are pathological changes can shed...
Dysbiosis is associated with pediatric and adult-onset inflammatory bowel disease (IBD), but the role of dysbiosis microbiome in very early onset IBD (VEO-IBD) has not yet been described. Here, we aimed to demonstrate impact age inflammation on microbial community structure using shotgun metagenomic sequencing children VEO-IBD, pediatric-onset IBD, age-matched healthy controls (HC) observed longitudinally over course 8 weeks. We found disease-related differences alpha beta diversity between...
Abstract Background Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBD-U) are scarce. We aimed to evaluate the effectiveness and safety of as an induction pediatric UC IBD-U. Methods In this multicenter retrospective study, treated for remission active IBD-U from 30 centers worldwide were enrolled. Demographic, clinical laboratory data well adverse events (AEs) recorded at week 8 post induction. Results One hundred included...
Introduction Therapeutic options are critically needed for children with refractory very early onset inflammatory bowel disease (VEO-IBD). Our aim was to evaluate clinical response canakinumab, an anti-IL-1β monoclonal antibody, in patients VEO-IBD whose phenotype resembles those monogenic autoinflammatory disease. Methods This is a single center retrospective study of (AIP) the absence identified treated canakinumab >6 months. AIP defined as confirmed IBD associated signs systemic...
Children with inflammatory bowel disease [IBD] are disproportionally affected by recurrent Clostridioides difficile infection [rCDI]. Although faecal microbiota transplantation [FMT] has been used good efficacy in adults IBD, little is known about outcomes associated FMT paediatric IBD.We performed a retrospective review of at 20 centres the USA from March 2012 to 2020. and without IBD were compared determined differences for rCDI. In addition, children successful outcome predictors success....
Abstract Background and Aims Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBD-U) are scarce. We aimed to evaluate the effectiveness safety of as an induction pediatric UC IBD-U. Methods In this multicenter retrospective study, treated for remission active IBD-U from 30 centers worldwide were enrolled. Demographic, clinical laboratory data well adverse events (AEs) recorded at week 8 post induction. Results One hundred...
Very early onset inflammatory bowel disease, diagnosed in children ≤5 years old, can be the initial presentation of some primary immunodeficiencies.In this study, we describe a 17-month-old boy with recurrent infections, growth failure, facial anomalies, and disease. Immune evaluation, whole-exome sequencing, karyotyping, methylation array were performed to evaluate child's constellation symptoms examination findings.Whole-exome sequencing revealed that child was homozygous for novel variant...